Last updated: 2026-10-15 08:10:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Neuronetics, Inc. (STIM) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $1.89, with a market capitalization of $151.63M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.80 to $3.44. This page covers its latest market performance, valuation, price trends and company information.
$151.63M | |
$1.95 | |
$39.39 | |
$0.52 | |
$1.99 | |
759.53K | |
1.85M | |
-- | |
$3.44 | |
$0.80 | |
-- | |
-- |
Neuronetics, Inc. (STIM) is trading at $1.97 in pre-market trading as of 2026-10-14 23:56:00, down 1.06% ($0.02) from the previous close of $1.99
Pre-market trading shows how investors are pricing STIM before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Neuronetics, Inc. (STIM) moved from $2.21 to $1.89, representing a decline of 14.71% ($0.32).
The stock traded between $1.88 and $2.28 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 619.73 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 41.1%
STIM is currently trading at $1.89, placing it 41.1% of the way from its 52-week low of $0.80 to its 52-week high of $3.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 658 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Neuronetics, Inc. (STIM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.